Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
3(60%)

Phase Distribution

Ph phase_4
2
40%
Ph not_applicable
2
40%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(3)

Detailed Status

Terminated3
Completed2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
40.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 42 (40.0%)
N/A2 (40.0%)

Trials by Status

completed240%
terminated360%

Recent Activity

Clinical Trials (5)

Drug Details

Intervention Type
PROCEDURE
Total Trials
5